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Since 1986, interferon-alfa (IFN-α) monotherapy has been administered for patients with chronic hepatitis C (CHC). However,
sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN-α was a major
breakthrough in the treatment of CHC. Sustained virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1
(HCV-1) patients, and is about 65% in HCV-2 or -3 patients. After 2000, pegylated interferon (PegIFN) much improved the rates
of SVR. Presently, PegIFN-α-ribavirin combination therapy has been current standard of care for patients infected with HCV. In
patients with HCV-1, treatment for 48 weeks is optimal, but 24 weeks of treatment is suﬃcient in HCV-2 or -3 infected patients.
Clinical factors have been identiﬁed as predictors for the eﬃcacy of the IFN-based therapy. The baseline factor most strongly
predictive of an SVR is the presence of HCV-2 or -3 infections. Rapid virological response (RVR) is the single best predictor of
an SVR to PegIFN-ribavirin therapy. If patients can’t achieve a RVR but achieve a complete early virological response (cEVR),
treatment with current standard of care can provide more than 90% SVR rate. HCV-1 patients who do not achieve an EVR should
discontinue the therapy. Recent advances of protease inhibitor may contribute the development of a novel triple combination
therapy.
1.Introduction
Interferon-alfa (IFN-α) monotherapy has been found with
normalization of alanine aminotransferase (ALT) levels in
a few patients diagnosed as non-A, non-B hepatitis even
before hepatitis C virus (HCV) was identiﬁed as the chief
etiologic agent in this diagnosis [1]. In 1989, the ﬁrst cases
of successful treatment of documented chronic hepatitis
C (CHC) with IFN-α monotherapy were reported, but
relapse after the cessation of treatment was common [2,
3]. The introduction of combination therapy with IFN-α
and ribavirin has markedly improved treatment response.
Nevertheless, less than one-half of patients with CHC were
able to experience a favorable response to the combination
therapy [4–6]. Since 2000, the attachment of inert polyethy-
leneglycoltoconventional IFN-α,pegylat edIF N -α(PegIFN-
α), reduced degradation and clearance, prolonging the half-
life of IFN and permitting less frequent, weekly dosing
while maintaining higher sustained IFN levels (compared
with 3 times weekly for conventional IFN). Now, PegIFN-
α-ribavirin combination treatment has been recommended
for all patients infected with HCV. For patients infected with
HCV genotype 1 (HCV-1), the recommended treatment
duration is 48 weeks, whereas for patients infected with
HCV-2 or HCV-3, the recommended treatment duration is
24 weeks [7].
2. ApprovedAgentsforTreatmentofHepatitisC
2.1. IFN-α. IFNs are natural cellular proteins with a variety
of actions. There are two distinct but complementary
mechanisms for the antiviral eﬀects of IFN-α: (a) induction
of a non-virus-speciﬁc antiviral state in infected cells,
resulting in direct inhibition of viral replication, and (b)
immunomodulatory eﬀects that enhance the host’s speciﬁc
antiviral immune responses and may accelerate the death
of infected cells [8]. A number of diﬀerent IFNs have been
used [9]. The U.S. Food and Drug Administration (FDA)
has approved 3 IFN preparations for treatment of HCV: (a)
3 million units (MUs) IFN-α-2a 3 times weekly; (b) 3 MUs2 Hepatitis Research and Treatment
of IFN-α-2b 3 times weekly; and (c) 9μgs of IFN alfacon-1
twice weekly, or 15μg 3 times weekly in nonresponders [10].
2.2. Peginterferon (PegIFN). PegIFN is a product of pegyla-
tion to conventional IFN (the attachment of inert polyethy-
lene glycol (PEG) polymers to a therapeutic protein such as
IFN). The larger molecular size of the compound results in
a longer half-life due to reduced clearance, while retaining
biological activity, and allows more convenient once-weekly
dosing. Two PegIFNs [11, 12] were studied: (a) PegIFN-α-
2a, a 40kDa branched molecule with a terminal half-life of
80 hours (range: 50–140 hours) and a mean clearance of
22mL/hr·kg administered at a ﬁxed 180μgp e rw e e ka n d
(b) PegIFN-α-2b, a 12kDa linear molecule with a mean
terminal half-life of 40 hours (range: 22–60 hours) and a
mean clearance of 94mL/hr · kg, administered on the basis
of weight (1.5μg/kg/week). Maximal serum concentrations
(Cmax) occur between 15 and 44 hours post dose and
are sustained for up to 48–72 hours. These two PegIFNs
much improved the rates of SVR in comparison with their
nonpegylated counterparts [11, 12].
2.3. Ribavirin. Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazo-
le-3-carboxamide) is an oral purine nucleoside analogue
with broad activity against viral pathogens [13]. Clearance
of ribavirin is markedly reduced with renal insuﬃciency
[14]. The mechanism of action of ribavirin in CHC remains
controversial. Among the suggested, but not proven, roles
of ribavirin in the treatment of CHC are an immunologic
modulation through switching the T-cell phenotype from
type 2 to type 1; inhibition of host inosine monophosphate
dehydrogenase activity; depletion of intracellular guanosine
triphosphate pools; induction of mutational catastrophe;
or a moderate, transient, early direct antiviral eﬀect [15].
Ribavirin may lead to rapid and lethal mutation of virions
or depletion of intracellular guanosine triphosphate, which
is necessary for viral RNA synthesis [16]. Additionally,
ribavirin may act synergistically with IFN by upregulating
theactivityofdouble-strandedRNA-activatedproteinkinase
and enhances the action of interferon-alfa against hepatitis C
virus [17].
The most interesting clinical observation is that ribavirin
monotherapy had a minimal eﬀect on HCV viremia, despite
the fact that serum ALT levels were reduced signiﬁcantly
in a considerable proportion of patients with chronic HCV
infection [18]. However, the combination of ribavirin and
IFN provides a clinically synergistic anti-HCV eﬀect. Hence
it was proposed that ribavirin may exert its eﬀect on the
host immune response. Several studies on virus-speciﬁc T-
cell reactivity in association with IFN treatment have found
increased numbers of patients with CHC with demonstrable
HCV-speciﬁc Th responses either during treatment or after a
sustained therapeutic response. These ﬁndings raise the pos-
sibility that enhancement of HCV-speciﬁc T-cell reactivity
may be one mechanism for successful antiviral treatment.
HCV-speciﬁc T-cell reactivity was uncommon at baseline
but increased markedly during antiviral therapy, peaking
around treatment weeks 4–8 [19]. The main diﬀerence in
T-cell reactivity of patients treated with IFN-ribavirin was
a signiﬁcant decrease of the expression of IFN-Υ,w h e r e a s
INF-Υ expression was similar to that in patients receiving
IFN monotherapy. The greater eﬃcacy of ribavirin may exert
an anti-inﬂammatory eﬀect and may help reducing IFN-γ-
driven T-cell activation and liver damage [20].
3. Assessment of Treatment Response
forHepatitisC
In earlier studies, the primary end point for HCV therapies
was a biochemical response, deﬁned as the normalization
of ALT levels [2, 3]. The introduction of virologic assays to
detect HCV RNA further allows the assessment of a virologic
response, deﬁned as polymerase chain reaction- (PCR-)
seronegative (50IU/mL, or 100copies/mL) for HCV RNA.
Histological response has been assessed in some clinical
studies, but there is little indication for posttreatment biopsy
in clinical practice.
Four on-treatment and three patterns of oﬀ-treatment
virological responses to antiviral therapy for hepatitis C have
emerged over the past decade [21–23]. They include the
following:
(1) rapid virologic response (RVR): PCR-seronegative of
HCV RNA at week 4;
(2) early virologic response (EVR): there are two kinds
stratiﬁcations of EVR:
(a) complete EVR (cEVR): PCR-seronegative of
HCV RNA at week 12;
(b) partial EVR (pEVR): decrease of HCV RNA by
>2 log from baseline values at week 12;
(3) end-of-treatment virologic response (ETVR): PCR-
seronegative of HCV RNA at the end of therapy;
(4) virologic breakthrough: HCV RNA reappearance in
serum while still on treatment;
(5) sustained virologic response (SVR): PCR-seronegative
of HCV RNA 6 months after completing therapy;
(6) virologic Relapse: PCR-seronegative of HCV RNA at
the end of therapy, with return of circulating virus
after completion of therapy;
(7) nonresponders: persistently seropositive for HCV
RNA throughout treatment.
More than 97% of patients with SVR remain nonviremic
by PCR for the subsequent 5–14 years [24, 25]. These
patientsareregardedashavingahighprobabilityofadurable
biochemical, virologic, and histological response [26].
4. Evolution of IFN-Based Therapy for
ChronicHepatitisC
4.1. IFN-α Monotherapy. Until the 1990s, the only therapy of
proven beneﬁt for patients with CHC was IFN-α. Initially, a
6-monthcourseof3weeklyinjectionsof3MUsofIFN-αwasHepatitis Research and Treatment 3
approvedfortreatmentofCHC, andabiochemical response,
deﬁned as the normalization of ALT levels, was assigned as
the primary end point [2, 3]. IFN-α monotherapy suppresses
serum HCV RNA to undetectable levels and normalizes the
ALT level in 25% to 40% of CHC patients, usually within
the ﬁrst 2-3 months of treatment. However, these initial
responses to IFN-α monotherapy are usually transient, and
sustained response is documented in only about 8% to 9% of
patients [27].
WhenvirologicassaysfordetectionofHCVRNAbecame
available, the virological response rates were observed to
be lower than those reported with biochemical end points.
In the meta-analysis of IFN-α monotherapy [28], nor-
malization of ALT levels at the end of treatment and 6
months after stopping treatment was seen in 47% and 23%
of treated patients, respectively. ETVR and SVR, however,
were observed in only 29% and 8% of treated patients,
respectively. Improvement of eﬃcacy on CHC could be
achieved with higher doses and/or a longer duration of IFN-
α monotherapy. A doubling of the duration of therapy to 12
months increased the frequency of SVRs to approximately
20%. The best eﬃcacy/risk ratio was in favor of 3 MUs of
IFN-α 3 times weekly for at least 12 months in treatment-
na¨ ıve patients with CHC [27].
4.2. IFN-α and Ribavirin Combination Therapy. The intro-
duction of ribavirin in combination with IFN-α was a
major breakthrough in the treatment of CHC. Even though
ribavirin monotherapy was shown to be ineﬀective [18],
the rate of SVRs was 43% and 6% for the IFN-α-2a with
and without ribavirin combination [4], respectively, and
36% and 18% for the IFN-α-2b with and without ribavirin
combination [29]. A meta-analysis in 1995 showed that
the SVR rate was signiﬁcantly higher for IFN-ribavirin
combination therapy than for IFN or ribavirin monotherapy
(odds ratio [OR]: IFN-ribavirin versus IFN = 9.8; 95%
conﬁdence interval [CI] = l.9–50) [30].
Several landmark studies then followed and consis-
tently demonstrated the dramatically improved responses
to combination therapy, especially for HCV-2 or HCV-3
patients. In 1998, two multicenter randomized controlled
trials (RCTs) (one U.S. study and one international study)
totaling 1,744 previously untreated patients with compen-
sated CHC compared 24- and 48-week drug regimens of
IFN-α-2b monotherapy (3 MUs 3 times weekly) with those
of IFN-α-2b and ribavirin (1.000mg/day or 1.200mg/day
for patients weighing <75kg or >75kg, resp.) combination
therapy followed by 24 weeks of oﬀ-therapy followup [5, 6].
The overall SVR rates for 24 and 48 weeks of therapy were
33% and 41%, respectively, for patients receiving IFN-α-
2b-ribavirin, compared with SVR rates of 6% at 24 weeks
and 16% at 48 weeks IFN-α-2b monotherapy. In addition
to deﬁnitively showing the beneﬁt of combination therapy
over IFN alone, these studies made several other impor-
tant clinical points. First, a striking reduction in hepatic
inﬂammation was seen in sustained virological responders.
Second, the likelihood of response to treatment was related
to pretreatment virus level and genotype. SVRs to 48 or
24 weeks of combination therapy occurred in 29% and
17% of HCV-1 patients, respectively, and in 65% and 66%
of HCV-2 or HCV-3 patients. The two studies reinforced
the importance of longer duration therapy for 48 weeks
in patients with HCV-1 infection. Similarly, SVRs to 48
or 24 weeks of combination therapy occurred in 38% and
27% of patients with pretreatment HCV RNA levels of
greater than 2 × 106 copies/mL, respectively, but the SVR
r a t e sw e r en od i ﬀerent for those with lower levels (45%
and 43%, resp.). A systematic review in 2001 included data
from15trialsinwhichpatientsreceivedIFN-αmonotherapy
or IFN-α-ribavirin combination therapy. In comparison
with IFN-α monotherapy, combination therapy reduced the
nonresponse rate (absence of SVR) by 26% in treatment-
na¨ ıve patients (relative risk = 0.74; 95% CI = 0.70–0.78).
Morbidity and mortality showed a nonsigniﬁcant trend
during treatment in favor of combination therapy.
In 1998, the FDA approved the combination of IFN-
α and ribavirin for patients with chronic HCV infection.
In 1999, the EASL International Consensus Conference on
Hepatitis C recommended that, for patients with CHC who
havenotbeenpreviouslytreated,(a)standardtherapyshould
consist of IFN-α and ribavirin in combination for 24 weeks
and that (b) treatment should be extended to 48 weeks in
patients with both HCV-1 and HCV RNA levels greater than
2 × 106 copies/mL [31].
4.3. PegIFN-α Monotherapy. Four RCTs compared the eﬃ-
cacy and safety of once-weekly PegIFN-α monotherapy
compared with IFN-α monotherapy three times per week
for the treatment of chronic HCV infection in treatment-
na¨ ıve patients [11, 12, 32, 33]. The initial studies of PegIFN-
α evaluated the dose-ranging eﬃcacy of monotherapy. The
recommended dose of PegIFN-α-2a monotherapy, admin-
istered ﬁxed at 180μg/week for 48 weeks, achieved higher
SVR rates compared with IFN-α-2a monotherapy (30% to
39% versus 8% to 19%) [12, 32, 33]; the PegIFN-α-2b
monotherapy, administered according to body weight at
1.5μg/kg/week for 48 weeks, achieved an SVR rate of 23%,
compared to 12% with IFN-α-2b monotherapy [11].
Ofnote,Heathcoteetal.[32]conductedtheﬁrstsubstan-
tiveprospectivestudyconﬁnedtopatientswithcompensated
cirrhosis or advanced ﬁbrosis. Cirrhosis has been a poor
predictor of responsiveness and is associated with a high
risk of leucopenia and thrombocytopenia [5, 6]. This study,
however, showed that PegIFN monotherapy was both well
tolerated and eﬀective in cirrhotic CHC patients, with an
S V Rr a t eo f3 0 % .
PegIFN monotherapy has been recommended for
patients with contraindications to ribavirin, such as those
with renal insuﬃciency, hemoglobinopathies, and ischemic
cardiovascular disease. Some clinical trials have been
reported to date in these populations [34, 35]. For patients
with contraindications to ribavirin but who have indications
for antiviral therapy, PegIFN represents the best option of
treatment.
4.4. PegIFN-α and Ribavirin Combination Therapy. The
results of PegIFN-α monotherapy encouraged more clinical4 Hepatitis Research and Treatment
trials to go on and anticipation that combination therapy
with PegIFN-α and ribavirin would be even more eﬀective.
The earlier two large RCTs were applied with ﬁxed durations
of 48 weeks [36, 37]. In these trials, PegIFN-α-2b was dosed
by weight (1.5μg/kg was FDA approved) and coupled with
800mg of ribavirin; PegIFN-α-2a was given at a ﬁxed dose of
180μg along with a weight-adjusted, higher dose of ribavirin
(1.000mg/day or 1.200mg/day for patients weighing <75 kg
or >75kg, resp.). The overall response rate in clinical trials
was 54% to 56%. These trials demonstrated that higher SVR
rates could be achieved with the combination of PegIFN-
α weekly plus oral ribavirin given twice daily than with the
combination of IFN-α given 3 times weekly plus ribavirin or
than with PegIFN-α monotherapy.
The issue of inﬂuence of ribavirin dose by body weight
on the response rate was ﬁrst addressed. In the PegIFN-
α-2b study, a post hoc analysis demonstrated that an SVR
of 61% was achieved in the subgroup whose daily dose of
ribavirin exceeded 10.6 mg/kg. Logistic regression analyses
observed that the response rates generally increased as
ribavirin dose increased up to about 13mg/kg/day. Actually,
the optimal ribavirin dose has not been deﬁned. Some
studies highlighted the potential importance of higher doses
of ribavirin [38, 39]. The ﬁrst 4 weeks of weight-based
ribavirin exposure (>13mg/kg/day) have been associated
with the achievement of an RVR [40]. In non-RVR patients,
oneposthocanalysisshowedthatprovidingandmaintaining
optimal dose of ribavirin within 12 weeks of treatment
was pivotal for the attainment of a cEVR [41]. Patients
with a cEVR in this study received a ribavirin dose of
16.3mg/kg/day. Moreover, a higher weight-based dose of
ribavirin(15.2mg/kilogram/day)wasassociatedwithalower
relapse rate and higher SVR rate [42].
Later, the optimal treatment duration and ribavirin dose
were investigated in a multicenter RCT in which all CHC
patients received PegIFN-α-2a at a dose of 180μg, while
patients in the four arms received either 24 or 48 weeks of
ribavirin at a dose of 800 mg or at the higher, weight-based
doses of 1.000 or 1.200mg daily [43]. In the subsequent
registration trial, a high frequency of SVRs occurred in
patients with HCV-2 or HCV-3, regardless of the regimen
(79% to 84%), but optimal frequencies of SVRs in HCV-
1 (52%) required longer duration and full-dose ribavirin,
independent of the level of HCV RNA. In patients with
HCV-1 with a low viral load (<2 × 106 copies/mL, or
800.000IU/mL), the SVR was highest in those who had
received the higher ribavirin dose and who were treated for
48 weeks (61%). This regimen was also optimal for patients
with HCV-1 and a high viral load (SVR rate: 46%). In
contrast, in patients with HCV-2 or HCV-3, regardless of
the pretreatment viral load, no diﬀerences were detected
with the 4 treatment regimens. Another single-arm, open-
label, historical-control study of 24 weeks of treatment with
PegIFN-α-2b plus ribavirin limited to patients with HCV-
2 or HCV-3 demonstrated that 24 weeks of treatment was
suﬃcient in HCV-2- or HCV-3-infected patients, with an
overallSVRrateof81%[44].Thisstudysupportsthecurrent
recommendationsthatpatientswithHCV-1require48weeks
of PegIFN-α therapy with higher doses of ribavirin, while
patients with HCV-2 or HCV-3 can be treated for only 24
weeks and with only 800mg daily of ribavirin [7, 45].
So far, there are 3 RCTs to compare the rates of SVR
of these two PegIFNs. One RCT showed no signiﬁcant
diﬀerence between the two available peginterferon-ribavirin
regimens in patients infected with HCV genotype 1 [46].
TwoRCTsshowedthatSVRratesweresigniﬁcantlygreaterin
HCVpatientstreatedwithPegIFN-α-2athanpatientstreated
with PegIFN-α-2b [12, 47, 48]. One recent meta-analysis
showed that peginterferon alpfa-2a signiﬁcantly increased
the number of patients who achieved a sustained virological
response (SVR) versus peginterferon alfa-2b (47% versus
41%; risk ratio: 1.11; 95% conﬁdence interval: 1.04–1.19;
P = .004 (eight trials)) [49].
4.5. Contraindication and Adverse Events of IFN-Ribavirin
and Management. Contraindications and adverse events of
IFN-ribavirin therapy are listed in Table 1. Physicians should
look speciﬁcally for contraindications to antiviral therapy
and assess both therapeutic risk and beneﬁt. Ribavirin is
contraindicated in pregnancy, necessitating strict precau-
tions and contraception in women of childbearing age and
their sexual partners and in HCV-infected men with female
partners of childbearing age. Flu-like side eﬀects of IFN
can be managed with acetaminophen or nonsteroidal anti-
inﬂammatory drugs; antidepressants and hypnotics can be
used for depression and insomnia, respectively. For manage-
ment of neutropenia, dose reduction suﬃces; the addition
of granulocyte colony-stimulating factor is generally not
recommended, although it may be considered in individual
cases of severe neutropenia. Treatment with ribavirin should
beavoidedinpatientswithischemiccardiovascularandcere-
brovascular disease and in patients with renal insuﬃciency.
If anemia occurs, options include ribavirin dose reduction or
the addition of erythropoietin. Patients with decompensated
cirrhosis are at high risk of adverse events and relatively
contraindicated to IFN-ribavirin.
Patients receiving combination therapy had an increased
risk for requiring medication dose reduction (RR = 2.44;
95% CI = 1.58–3.75) or discontinuation (RR = 1.28;
95% CI = 1.07–1.52) compared with those receiving IFN
monotherapy [50]. The rates of IFN dose reduction and dis-
continuation were similar among subjects receiving PegIFN
and conventional IFN [11, 12].
5.FactorsAssociatedwithTreatmentEfﬁcacy
With the great progress in the management of CHC, clinical
factors have been identiﬁed as predictors for the eﬃcacy of
theIFN-basedtherapy.Theycouldbedividedintotwomajor
categories: baseline and on-treatment predictors (Table 2).
5.1. Baseline Predictors of Response to IFN-Based Therapy
5.1.1. Virologic Factors. The pretreatment variable most
strongly predictive of an SVR is the presence of HCV-2 or
HCV-3 infection [51], whether with conventional IFNs or
PegIFNs, alone or in combination with ribavirin [5, 6, 36,
37]. On the basis of variations in the nucleotide sequenceHepatitis Research and Treatment 5
Table 1: Contraindications and adverse eﬀects of hepatitis C therapy.
Contraindications
Absolute contraindications
Major, uncontrolled depressive illness; autoimmune hepatitis or other condition known to be
exacerbated by interferon and ribavirin; untreated hyperthyroidism; pregnant or
unwilling/unable to comply with adequate contraception; severe concurrent disease such as
severe hypertension, heart failure, signiﬁcant coronary artery disease, poorly controlled diabetes,
obstructive pulmonary disease; under 3 years of age; known hypersensitivity to drugs used to
treat HCV
Relative contraindications
Decompensated liver disease; solid organ transplantation (except liver); coexisting medical
conditions: severe anemia (hemoglobin level < 100g/L), neutropenia (neutrophil count < 0.75 ×
109/L), thrombocytopenia (platelet count < 40 × 109/L), hemoglobinopathy, uncontrolled heart
disease (angina, congestive heart failure, signiﬁcant arrhythmias), cerebrovascular disease,
advanced renal failure (creatinine clearance < 50mL/min)
Adverse eﬀects
Interferon or peginterferon
Flu-like symptoms (fever, fatigue, myalgia and headaches); mild bone marrow suppression
(especially, leucopenia and thrombocytopenia); gastrointestinal manifestation (anorexia, nausea,
vomiting and diarrhea); emotional eﬀects (depression, irritability, diﬃculty concentrating,
memory disturbance and insomnia); dermatological manifestation (skin irritation, rash and
alopecia); autoimmune disorders (especially thyroid dysfunction); weight loss; tinnitus and
hearing loss; retinopathy (usually not clinically signiﬁcant); hyperglycemia; seizures; renal
function impairment; pneumonitis.
Ribavirin Hemolytic anemia (dose dependent); cough and dyspnea; rash and pruritis; nausea; sinus
disorders; teratogenicity.
Table 2: Factors associated with response to interferon-based
therapy for hepatitis C.
Baseline
Virological factors
Hepatitis C virus genotype










Host genetics: genetic variation in IL28B
Coinfection with HIV
Nonresponse to previous interferon-based therapy
On-treatment
Rapid virological response (RVR) at week 4
Early virological response (EVR) at week 12
C o m p l e t eE V R( c E V R )v e r s u sP a r t i a lE V R( p E V R )
Medical adherence
of HCV, six genotypes (numbered 1–6) and more than 50
subtypes (identiﬁed by lowercase letters, e.g., 1a and 1b)
have been identiﬁed [52]. Why HCV-1 is harder to treat
than other HCV genotypes is not yet fully understood.
Several studies demonstrated that there exists a genotype-
speciﬁc diﬀerence of viral kinetics [23, 53]. The turnover
of hepatocytes infected with HCV-1 is slower than that
of hepatocytes infected with other HCV genotypes after
initiation of IFN-based therapy [53, 54], implying that
HCV-1 might be more resistant to antiviral therapy. Under
the current recommendation [7], SVR rates were 42% to
60% for HCV-1 infection with a 48-week PegIFN-ribavirin
treatment, compared with 76% to 95% for HCV-2 or HCV-
3 infections with a 24-week regimen [23, 36, 37, 43, 44,
55, 56]. Patients with HCV-4, which is common in Egypt,
are intermediate in responsiveness to therapy between those
infected with HCV-1 and HCV-2 or HCV-3, and it is
suggested that they should be treated for a full 48 weeks with
full-dose ribavirin, like patients with HCV-1 [4, 41]. There
is insuﬃcient experience to provide recommendations for
the treatment of persons with HCV-5 and HCV-6 so far.
Experienced providers need to make treatment judgments
on a case-by-case basis. Since HCV genotype is the strongest
predictor of responses to IFN-based therapy for CHC, it
should be determined in all HCV-infected persons prior
to treatment to determine the duration of therapy and the
likelihood of response [7].
Pretreatment HCV RNA level, even less important than
HCV genotype, is a predictor of sustained response in IFN-
based therapy [5, 6, 11, 37, 57]. A higher HCV RNA level
predicts a lower response rate. The impact of HCV RNA
level on the response to combination therapy was diﬀerent
between patients with diﬀerent HCV genotype infections.
High viral load (with a cutoﬀ value of 200.000copies/mL,
or 40.000IU/mL) inﬂuenced the response rate in patients
with HCV-1 (41% versus 56%) but not those in patients
with HCV-2 or HCV-3 (74% versus 81%) [36]. Under6 Hepatitis Research and Treatment
the circumstances of a determined HCV genotype for
CHC patients, testing HCV RNA levels is beneﬁcial and
recommended for HCV-1 patients but seems variable for
HCV-2 or HCV-3 patients [7].
HCV viral quasispecies evolution is considered another
key element determining treatment response [58]. Higher
quasispecies complexity at baseline has been observed in
nonresponders than in sustained virological responders
[59]. An increasing number of mutations within the car-
boxyl terminal region of the HCV nonstructural 5A pro-
tein, named the IFN-sensitivity-determining region (ISDR),
were correlated with treatment response in HCV-1-infected
patients [60]. Patients infected with the so-called mutant
type, deﬁned by four or more amino acid substitutions
in the ISDR, showed a more favorable response toward
IFN-based therapy in Japan and Taiwan [60, 61]. However,
these ﬁndings were not observed in a European study [62].
Additionally, a high degree (≥6) of sequence variation in
the variable region 3 (V3) plus its upstream ﬂanking region
of NS5A (amino acid 2334–2379), referred to as IFN/RBV
resistance-determining region (IRRDR), would be a useful
marker for predicting SVR, whereas a less diverse (≤5)
IRRDR sequence predicts non-SVR [63].
5.1.2. Host Factors. The presence of bridging ﬁbrosis and
cirrhosis has been reported as one of the most unfavorable
predictors for IFN-based therapy [5, 6, 12, 51, 64, 65].
Patients with cirrhosis generally respond poorly to standard
IFN monotherapy, with SVR rates of 5% to 20% [6, 32].
Responses are improved when conventional IFNs or PegIFNs
are combined with ribavirin, resulting in SVR rates of 33%
to 44% [6, 36, 37].
Ag e n d e re ﬀect on response has been reported. Female
sex was a predictor of SVR in studies of conventional IFN-
basedtherapy[51],butnotinthestudiesofPegIFN-ribavirin
[11, 36, 43]. Younger patients (<40 years) had higher
SVR rates with PegIFN-ribavirin [36, 37, 43]. Sustained
responders were younger than nonresponders by an average
of 5 years [66].
Several studies have demonstrated that SVR rates are
lower in patients with coexistent insulin resistance and/or
hepatic steatosis or steatohepatitis [67, 68]. In HCV-1
patients treated with PegIFN-ribavirin, a lower SVR rate
wasobservedinpatientswithinsulinresistance(homeostasis
model of assessment, HOMA-IR > 2) compared to those
without insulin resistance [69, 70].
CHC patients with body mass indexes >30kg/m2 are
more likely to be insulin-resistant, to have more advanced
hepatic steatosis or steatohepatitis and ﬁbrosis, and to
experience a reduced response to combination therapy
[71, 72]. Additionally, other possible mechanisms of the
impact of obesity on the therapeutic response include the
linear correlation of eﬃcacy and body-weight-based doses
of ribavirin (10.6–15mg/kg/day) [37]. To encourage weight
loss and exercise before treatment, which has been associated
with a reduction in steatosis ﬁbrosis scores, is the most direct
approach for formulating more eﬀective treatment regimens
[73].
Excessive alcohol use could reduce the likelihood of a
response to therapy [74, 75]. To increase the eﬃcacy of
antiviral therapy, it has been suggested that abstinence be
recommended before and during treatment for CHC [45].
Racial diﬀerences in response to eﬃcacy of IFN exist
and have been one of the host factors. A lower response
rate to IFN monotherapy was observed among African-
American patients compared with White patients [17, 76].
A pool analysis of two clinical trials with IFN-ribavirin
combination therapy demonstrated that SVRs were highest
among Asians (61%), followed by Whites (39%), Hispanics
(23%), and African-Americans (14%) [77]. Hispanics and
African-Americans were less likely to respond to PegIFN-α-
ribavirin compared to Whites [78]. In studies of Taiwanese
CHCpatients,theSVRratewas23.7%,37.1%,and63.6%for
a24-weektreatmentof3MUsofIFN-α3timesweeklyalone,
6 MUs of 3 times weekly alone, and 3 MUs of 3 times weekly
plus ribavirin, respectively [65, 79]. The SVR rate of HCV-1b
patients to 24-week PegIFN-α-ribavirin was 48.9% to 65.8%
and could be as high as 80% with a 48-week regimen in
Taiwan [79, 80]. A relative lower body weight (67–70kg) in
AsianpatientscomparedtoU.S.patients(78–81kg)mayalso
play an important role [71].
The diﬀerent ethnic response rates may reﬂect the
important role of genetics. Host genetic variations are
probably involved in the eﬃcacy of IFN-based therapies
for CHC [81]. Genetic polymorphisms of human leukocyte
antigen, CC chemokine receptor 5, cytotoxic T lymphocyte
antigen-4,interleukin-10,lowmolecularmasspolypeptide7,
MxA,andtransforminggrowthfactor-β1ha v ebeenr eport ed
to have signiﬁcant associations with responsiveness [82–
89]. TNF-α-308 polymorphism was associated with SVRs
to IFN-ribavirin in patients with HCV-1b infection and a
high viral load [90]. These results reﬂect the important role
of unique genetic predisposition, at least in part, in the
response to IFN-based therapy for CHC. Recent advances
in pharmacogenomics have demonstrated the potential
applications of genetic single nucleotide polymorphism and
expression patterns in determining treatment responsiveness
in CHC [91, 92]. A recent candidate gene study showed
that genetic variation in the IL28B gene, which encodes
IFN-λ3, is associated with spontaneous HCV clearance [93].
Several genome-wide associated studies observed that IL28B
single nucleotide polymorphisms played an important role
in the treatment outcome of PegIFN-RBV for CHC [94–96].
A genome-wide association study in 2010 conﬁrmed that
IL28B genetic variation was the strongest genetic predictor
in both natural and treatment-induced control of HCV. No
SNPoutsidetheIL28B/Alocusreachedgenome-widesigniﬁ-
cance[97].TheincreasingevidencefortheroleofIFN-λ3for
both spontaneous and treatment-induced control of HCV
infection opens new avenues for prognosis and treatment of
HCV infection. Individuals with HCV genotype 1 or 4 who
carry the risk allele, particularly in homozygosis, will have a
very low probability of natural or treatment-induced clear-
ance. These individuals would be prime candidates for novel
therapeutic strategies [97]. Half of the ethnic diﬀerences in
response to interferon and ribavirin combination therapy
can be explained by genetic polymorphism of IL28B [94].Hepatitis Research and Treatment 7
Becauseofthepresumablysharedroutesoftransmission,
approximatelyone-fourthtoone-thirdofallpersonsinfected
with HIV are coinfected with HCV [98]. Patients with HIV-
HCV coinfection have been shown to respond less favorably
to antiviral therapy than patients infected with HCV alone
[98, 99]. Several RCTs recommended 48 weeks of PegIFN-
ribavirinforHCV,regardlessofHCVgenotype,inHCV-HIV
coinfected patients [100, 101].
Dual infections of HCV and hepatitis B virus (HBV)
a r en o tu n c o m m o na n do c c u ri nu pt o5 %o ft h eg e n e r a l
population in HCV-endemic areas [102]. Combined chronic
hepatitis B and C leads to more severe liver disease and
an increased risk of HCV [103]. Although HBV-HCV dual
infection was refractory to conventional IFN monotherapy
[104], recent studies in Taiwan have demonstrated that con-
ventional IFN-ribavirin combinationtherapy waseﬀectivein
HCV clearance among HCV-dominant, HBV/HCV dually
infected patients [105, 106]. Recently, a large, open-label,
comparative, multicenter study conﬁrmed the eﬃcacy of
PegIFN-ribavirin for patients with chronic HCV-HBV dual
infection in Taiwan [107].
Nonresponders are more resistant to retreatment with
subsequent IFN-based therapy, compared to relapsers (OR
= 3.912; 95% CI = 1.459–10.49) [108]. Retreatment with
PegIFN-ribavirin could achieve an SVR rate of 47% to 60%
for relapsers and 18% to 23% for nonresponders [109–112].
5.2. On-Treatment Predictors and Response-Guided Individ-
ualized Therapy. During IFN-α-based therapy, HCV RNA
levels generally fall in a biphasic manner [74]. The ﬁrst
rapid phase of viral suppression, from a few hours after the
ﬁrst IFN-α injection to the end of the ﬁrst day, is related
to an inhibition of viral replication by a direct, nonspeciﬁc
action of IFN-α. This early initial decline in HCV RNA
levels correlates poorly with the eventual response to IFN-
based therapy [74, 113]. The second, slower phase of viral
suppression, beginning on day 2 and gradually leading to
seroclearance of HCV RNA, is possibly related to the gradual
clearance of infected cells by the patient’s immune system,
whileHCVreplicationiseﬃcientlyinhibited.Thisphase,less
inﬂuenced by the dosage of IFN and HCV genotype, exhibits
a good response to PegIFN and is an excellent marker of an
SVR to the treatment [36, 54, 74].
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with a high degree of accuracy in both HCV-1 and HCV-
2 patients, with positive predictive values of 78% and 92%,
respectively [23]. Recent studies have demonstrated that an
RVR is the single best predictor of an SVR to PegIFN-
ribavirin for HCV-1 [114, 115] and HCV-2 or HCV-3
patients[23,55,56,116].ForHCV-1orHCV-4patientswith
lower baseline viral loads and an RVR, an abbreviated 24-
week regimen could achieve a comparable SVR rate with a
standard 48-week regimen [115, 117, 118]. Selected patients
with RVR might have their treatment courses abbreviated to
16 weeks if they are infected with HCV-2 or HCV-3 [23, 56].
But, the shortening of therapy duration for genotype 2/3
with RVR is still controversial [119]. Abbreviated regimens
may be considered in patients with a low baseline viral load
who achieve an RVR [120, 121].
Among patients with an EVR, the likelihood of an SVR
is only 72% [22]. However, as a negative predictor, non-EVR
is even an more robust predictor. In cases without an EVR,
the likelihood of an SVR is approximately 0% to 2% [122].
In Taiwan, the non-EVR is a signiﬁcantly negative predictor
in HCV-1 patients, but not in HCV-2 patients [23]. Thus it
is recommended that HCV-1 patients who do not achieve
an EVR at week 12 should discontinue the therapy beyond
12 weeks [22, 78]. Recently, stratiﬁcation of early virological
response (EVR) into complete EVR (cEVR) and partial EVR
(pEVR) has been possible to further improve the prediction
of an SVR and may allow for optimizing treatment duration
in non-RVR patients [123]. Studies for HCV-1 non-RVR
patients have demonstrated that the current recommended
48 weeks of treatment could achieve high SVR rates in
patients with a cEVR but could lower rates of SVR in patients
with a pEVR [124, 125]. The SVR rates would be more than
90% if patients could reach a cEVR with a standard regimen
(48 weeks for HCV-1 or 24 weeks for HCV-2) [41]. For
non-RVR patients, HCV viral loads <104 IU/mL at week 4
provided an early and accurate prediction of who would or
would not achieve a cEVR and following SVR [41]. In HCV-
1-infectedpatientswithapEVR,theSVRrateswere10%and
21% only and the relapse rates were up to 83% and 63% in
the24-weekand48-weekgroups,respectively.Thetreatment
responses were inadequate, even with a standard 48-week
regimen in these patients [124, 125].
Based on these predictors associated with treatment
eﬃcacy, response-guided individualized therapy has become
a major consideration for clinicians. It is desirable to expose
CHC patients to the lowest doses and shortest durations
of treatment, to reduce the likelihood of adverse events
and to minimize costs, without compromising treatment
eﬃcacy. On the other hand, some diﬃcult-to-treat patients
have to receive longer and/or higher dose therapy to achieve
responses. To date, HCV genotype, baseline viral load
as well as on-treatment virological responses will provide
information for individualized therapy decisionmaking for
CHC patients in the near future [115, 126]. People who have
an RVR may have a chance to abbreviate their treatment
courses to avoid unnecessary costs and preventable drug side
eﬀects. In patients without an RVR treated with standard of
care, the SVR rate would be more than 90% if cEVR could
be accomplished. In patients with only a pEVR, it has been
suggested to extend the treatment course to 72 weeks [124,
125, 127] or adhere to high-dose peginterferon plus ribavirin
combination therapy [128]. In the future, additional therapy
other than interferon-based treatment, such as protease
inhibitors, might be anticipated in those diﬃcult-to-treat
patients. One would like to be able to evaluate whether
a treatment response is likely as early as possible so that
individualizedstrategiescanbemadeoralteredearlierbefore
or during the treatment course. HCV viral loads <104 IU/mL
at week 4 provided an accurate prediction of cEVR and SVR
in non-RVR patients [41].
Medical adherence is an important factor associated with
response to IFN-ribavirin, especially among patients with
HCV-1 infection. In a retrospective analysis of data collected
in the large registration trials of IFN-ribavirin, SVRs have8 Hepatitis Research and Treatment
been reported to be more likely in patients who had taken
at least 80% of all projected IFN injections and at least 80%
of all projected ribavirin for at least 80% of the anticipated
duration of treatment [39].
6.ProteaseInhibitorsandIFN-BasedTherapy
Recent development of direct-acting antiviral agents, also
named“speciﬁcallytargetedantiviraltherapyforhepatitisC”
(STAT-C) compounds, to treat HCV has focused predomi-
nantly on inhibitors of the viral enzymes NS3/4A protease
and the RNA-dependent RNA polymerase NS5B [129, 130].
NS5B polymerase inhibitors in general have a lower antiviral
eﬃcacy than protease inhibitors [130]. The administration
of HCV NS3/4A protease inhibitors to patients with chronic
HCV infections has demonstrated that they have dramatic
antiviral eﬀects and that compounds acting via this mech-
anism are likely to form a key component of future anti-
HCV therapy [131]. Newer data have demonstrated promise
for 2 protease inhibitors, SCH 503034 (boceprevir) and VX-
950 (telaprevir), both of which appear to be able to improve
sustained response while shortening duration of therapy
[132]. Telaprevir (VX-950), the HCV protease inhibitor, is
in the most advanced phase of clinical development [133].
A ﬁrst case of sustained virological response (SVR) achieved
in a patient with chronic hepatitis C by monotherapy with
telaprevir without interferon therapy was reported [134].
Owing to a low genetic barrier, resistant variants emerge
within a few days when used in monotherapy, thereby
decreasing its eﬃcacy. Consequently, telaprevir has been
combined with pegylated-interferon and ribavirin in clinical
trials. This triple combination is more eﬀective but has a
higherrateofadverseevents(notablyrash)thanthestandard
of care, despite the shorter duration of therapy [133]. Results
of the milestone studies PROVE 1 and 2 indicate that 12
weeks of telaprevir-based triple therapy is too short because
of the high rate of relapse after treatment completion.
However, 24 to 48 weeks of total therapy including 12 weeks
of triple therapy with telaprevir in addition to standard
treatment greatly improved SVR rates in treatment-na¨ ıve
genotype 1 patients compared with the standard of care.
PROVE 3 has shown that telaprevir is also highly eﬀective
in the treatment of prior nonresponders or relapsers infected
with HCV genotype 1 [130, 135].
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